Capsule
250 mg
Alkylating agent anticancer
Adult: 75 mg/m² daily for 42 days (concomitant with focal radiotherapy); followed by up to 6 cycles of monotherapy at 150 mg/m² for 5 days every 4 weeks. Weekly haematological and non-haematological toxicity criteria determine dose continuation or escalation.
Adult and children > 3 years: 200 mg/m² once daily for the first 5 days followed by a 23 day treatment interruption.
In patients previously treated with chemotherapy: the initial dose is 150 mg/m² once daily, to be increased in the second cycle to 200 mg/m² once daily, for 5 days if there is no haematological toxicity.